Inhibition of the CP55 940 supernatant-induced stimulation of fMLP-treated PMNs by preincubation with the COX inhibitor meclofenamic acid and the FLAP inhibitor MK886 Data are presented as a percentage of the cannabinoid-free control without COX and LOX inhibitors (resting PMN, 3.61% ± 0.61 rhodamine-positive cells; fMLP-stimulated PMN, 13.70% ± 1.11 rhodamine-positive cells). Mean ± S.E.M. of six independent triplicate experiments. Concentrations are given as final concentrations in the tests.
Without CP | 0.1 nM CP | |
|---|---|---|
| Rhod. pos. PMNs (% control) | ||
| No inhibitor | 100 | 241.85 ± 29.41 |
| 50 μM meclo | 93.84 ± 6.41 | 139.40 ± 4.84* |
| 100 μM meclo | 97.96 ± 3.64 | 109.92 ± 6.41* |
| 4 μM MK886 | 101.62 ± 18.34 | 149.99 ± 20.19 |
| 40 μM MK886 | 104.39 ± 6.49 | 168.47 ± 26.63 |
| Mean fluorescence | ||
| No inhibitor | 100 | 194.20 ± 63.71 |
| 50 μM meclo | 103.31 ± 2.46 | 121.80 ± 7.64* |
| 100 μM meclo | 100.66 ± 3.98 | 111.43 ± 8.47* |
| 4 μM MK886 | 106.74 ± 6.42 | 136.91 ± 11.68 |
| 40 μM MK886 | 109.21 ± 5.35 | 142.25 ± 11.48 |
Rhod. pos., rhodamine-positive PMN.
↵* P < 0.05, ANOVA